Two options now dominate the conversation about medical weight loss: bariatric surgery, which has been studied for decades, and GLP-1 medications such as semaglutide and tirzepatide, which are newer but increasingly common. People searching for a comparison usually want the same three answers: how much weight each approach takes off, how much of that weight is muscle, and what happens to the weight over the following years.
One caution up front: no single large trial has compared the two head to head over the long term. The numbers below come from different studies with different participants, so they are best read as general patterns rather than a scoreboard.
How Much Weight Each Approach Takes Off
GLP-1 medications. In the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), adults with obesity taking semaglutide 2.4 mg lost an average of about 15% of body weight over 68 weeks, compared with about 2.4% on placebo. In the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022), tirzepatide produced average losses of roughly 15% to 21% over 72 weeks depending on dose, compared with about 3% on placebo.
Bariatric surgery. The Swedish Obese Subjects (SOS) study followed 4,047 people for an average of 10.9 years, comparing 2,010 who had surgery with 2,037 matched controls who received conventional care. Weight loss peaked one to two years after surgery at about 32% for gastric bypass, then settled by year 10 at roughly 25% for gastric bypass, 16% for vertical banded gastroplasty, and 14% for gastric banding, while the control group's weight changed by less than 2% in either direction.
A later analysis of more than 129,000 Kaiser Permanente patients (Arterburn et al., Annals of Surgery, 2020) found that people who had gastric bypass maintained about 20% weight loss at 10 years, compared with about 5% in matched patients receiving usual medical care. Long-term data for sleeve gastrectomy, a newer procedure, were not yet available in that study.
What Happens to the Weight Over Time
After stopping GLP-1 medication. The STEP 1 extension (Wilding et al., Diabetes, Obesity and Metabolism, 2022) followed 327 participants for a year after treatment ended. Those who had taken semaglutide had lost an average of 17.3% of body weight on treatment and then regained 11.6 percentage points, about two-thirds of their prior loss. The cardiometabolic improvements seen during treatment, such as changes in blood pressure and blood sugar markers, also moved back toward baseline for most variables. The practical message from this trial is that for many people these medications work while they are taken, which is why clinicians increasingly describe obesity treatment as long-term rather than a short course.
After surgery. Surgery changes anatomy rather than requiring ongoing medication, and the SOS and Kaiser data show that substantial weight loss can persist for a decade or more. It is not regain-proof, however. A 10-year comparison of 253 adults (Tan et al., International Journal of Obesity, 2025) found average total weight loss of 21.0% after gastric bypass versus 15.4% after sleeve gastrectomy, and significant regain (20% or more from the lowest weight reached) in 13.7% of bypass patients versus 27.9% of sleeve patients. The type of procedure clearly matters, and regain after surgery is a real, documented outcome.
The Muscle Question
Any large weight loss, whether from diet, drugs, or surgery, includes some loss of lean mass (muscle plus other non-fat tissue). The question is how much, and whether it is unusual.
A DXA body-composition substudy of 160 SURMOUNT-1 participants (Look et al., Diabetes, Obesity and Metabolism, 2025) measured this directly. Over 72 weeks, people on tirzepatide lost 21.3% of body weight, including 33.9% of fat mass and 10.9% of lean mass. About 75% of the weight lost was fat and about 25% was lean mass, and the authors noted the same 75/25 split in the placebo group, who lost far less weight overall. In other words, the proportion looked similar to what is seen with other weight loss approaches, while the absolute amount of lean tissue lost was larger because the total loss was larger.
Surgery also involves loss of lean mass, particularly in the first year when weight drops fastest, and published body-composition studies report a meaningful share of the weight lost as fat-free mass, with considerable variation between people and procedures. The takeaway is the same for both approaches: protecting muscle takes deliberate effort, namely adequate protein, resistance training, and enough total nutrition, rather than assuming the method itself guarantees fat-only loss.
Side-by-Side Summary
| Factor | GLP-1 Medications | Bariatric Surgery |
|---|---|---|
| Typical average loss in trials | ~15% (semaglutide) to ~15-21% (tirzepatide) at 68-72 weeks | Peak ~30% with bypass; ~20-25% maintained at 10 years with bypass |
| What happens if treatment stops | About two-thirds of the loss regained within a year (semaglutide) | Not applicable; but regain can still occur over time, more often after sleeve than bypass in one 10-year study |
| Lean mass loss | ~25% of weight lost in the SURMOUNT-1 DXA substudy | Occurs, especially in year one; varies by person and procedure |
| Long-term mortality data | Still accumulating | SOS study: lower mortality after surgery (adjusted hazard ratio 0.71) |
| Nature of the intervention | Reversible, ongoing treatment; main side effects are gastrointestinal | Permanent anatomical change; surgical risks and lifelong nutrient monitoring |
The SOS study also found that people who had surgery had lower mortality than matched controls over about 11 years (adjusted hazard ratio 0.71), with 101 deaths in the surgery group versus 129 in the control group. This is an observational comparison rather than a randomized trial, so it shows an association rather than proof of cause, but it is among the strongest long-term data in the field.
Risks and Practical Trade-offs
Medications: The most common side effects reported in trials are gastrointestinal, including nausea, diarrhea, constipation, and vomiting, particularly when doses are increased. Ongoing cost, access, and the need to continue treatment to maintain results are significant practical considerations.
Surgery: As with any operation, there are surgical risks, and the procedures permanently alter digestion. People who have had bariatric surgery generally need lifelong follow-up and nutritional supplementation, since reduced stomach size and absorption can lead to deficiencies in nutrients such as vitamin B12, iron, calcium, and vitamin D over time.
Neither option removes the importance of the basics. Adequate protein, resistance training, and sleep support muscle preservation and long-term maintenance whichever route is used.
Who Typically Considers Which Option?
Eligibility and appropriateness depend on body mass index, related conditions such as type 2 diabetes, medical history, goals, and personal preferences, and the decision is individual. Some people use medication first, some choose surgery, and some use both at different stages. That choice is best made with a physician experienced in obesity medicine, often alongside a registered dietitian and, for surgery, a bariatric surgical team.
A Note on Using This Information
This article summarizes findings from published clinical research for general educational purposes and does not constitute medical advice, a recommendation for or against any treatment, or a substitute for professional evaluation. The studies cited involved different populations, durations, and designs, and their averages do not predict any individual's results. Individual outcomes, risks, and eligibility vary significantly based on age, health status, medications, and other factors that a general article cannot assess.
Do not start, stop, or change any prescription weight loss medication, and do not make decisions about bariatric surgery, based on this article alone. If you are considering either option, or if you currently take a GLP-1 medication and have questions about continuing or stopping, speak with your doctor or an obesity medicine specialist, who can evaluate your complete medical history. Seek prompt medical care for severe abdominal pain, persistent vomiting, signs of dehydration, or any other symptoms that concern you.
Primary sources referenced in this article:
1. Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1), New England Journal of Medicine, 2021: https://doi.org/10.1056/NEJMoa2032183
2. Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1), New England Journal of Medicine, 2022: https://doi.org/10.1056/NEJMoa2206038
3. Wilding JPH et al., "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension," Diabetes, Obesity and Metabolism, 2022: https://doi.org/10.1111/dom.14725
4. Look M et al., "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight," Diabetes, Obesity and Metabolism, 2025: https://doi.org/10.1111/dom.16275
5. Sjostrom L et al., "Effects of bariatric surgery on mortality in Swedish obese subjects," New England Journal of Medicine, 2007: https://doi.org/10.1056/NEJMoa066254
6. Arterburn D et al., long-term outcomes of bariatric surgery versus usual care in more than 129,000 patients, Annals of Surgery, 2020 (summary): Kaiser Permanente Washington Health Research Institute
7. Tan SYT et al., "Greater durability of weight loss at ten years with gastric bypass compared to sleeve gastrectomy," International Journal of Obesity, 2025: https://doi.org/10.1038/s41366-025-01760-2
Bariatric Surgery vs GLP-1, Bariatric Surgery vs Ozempic, Gastric Bypass vs Semaglutide, Sleeve Gastrectomy vs Wegovy, Weight Regain After Surgery, Weight Regain After Stopping Ozempic, GLP-1 Muscle Loss, Long-Term Weight Loss Results, Tirzepatide vs Bariatric Surgery, Swedish Obese Subjects Study, Obesity Treatment Options
Comments
Post a Comment